<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027677</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16007</org_study_id>
    <secondary_id>EORTC-16007</secondary_id>
    <secondary_id>COLLGARD-EORTC-16007</secondary_id>
    <nct_id>NCT00027677</nct_id>
  </id_info>
  <brief_title>Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Halofuginone hydrobromide may stop the growth of solid tumors by stopping blood&#xD;
      flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of halofuginone hydrobromide in treating&#xD;
      patients who have progressive advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity profile, maximum tolerated dose, and dose-limiting toxic effects&#xD;
           of halofuginone hydrobromide in patients with progressive advanced solid tumors.&#xD;
&#xD;
        -  Establish a recommended dose of this drug for phase II study.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive oral halofuginone hydrobromide once daily on days 1 and 4-14 of course 1 and&#xD;
      on days 1-14 of subsequent courses. Treatment repeats every 14 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-3 patients receive escalating doses of halofuginone hydrobromide until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 20% of&#xD;
      patients experience acute dose-limiting toxicity. After the MTD is reached, 6-12 additional&#xD;
      patients are treated at dose levels preceding the MTD until the recommended dose for phase II&#xD;
      study is determined. The recommended dose for phase II study is defined as the dose preceding&#xD;
      the MTD that allows a 90% dose intensity for 2 months with no greater than grade 2 toxicity&#xD;
      in 80% of the patients.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression or initiation of another&#xD;
      treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 7-40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>halofuginone hydrobromide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor that is not amenable to&#xD;
             any clinical improvement by current standard treatments&#xD;
&#xD;
               -  No tumors of the upper digestive tract&#xD;
&#xD;
          -  No clinical signs of CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  No unstable hepatobiliary disease that would preclude study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No unstable renal disease that would preclude study&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable cardiovascular disease (e.g., stroke) that would preclude study&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No unstable pulmonary disease that would preclude study&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No digestive disease, including upper gastrointestinal tract, that would hamper&#xD;
             absorption&#xD;
&#xD;
          -  No evident/known lactose malabsorption&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No allergy to components of the study drug&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other unstable systemic disease that would preclude study&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude compliance&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior anticancer hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since other prior anticancer treatment&#xD;
&#xD;
          -  No other concurrent anticancer agents or investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja De Jonge, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Daniel Den Hoed Cancer Center at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Rotterdam Dijkzigt</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Halofuginone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

